NAGE vs TLRY
Niagen Bioscience, Inc. and Tilray Brands, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NAGE | TLRY |
|---|---|---|
| Revenue | $129.4M | $915.5M |
| Net income | $17.4M | $-121.4M |
| Gross margin | 64.3% | 28.4% |
| Net margin | 13.4% | −11.5% |
| Return on equity | 28.3% | −7.8% |
| Diluted EPS | $0.20 | −$1.09 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | — | — |
| Equity | $76.5M | $1.6B |
| Net debt / equity | — | −0.13× |
| Current ratio | 4.86× | 2.21× |
| Revenue CAGR 5y | 16.9% | 12.3% |
| Profit CAGR 5y | — | — |
TLRY bills 7.1× the revenue of NAGE, and TLRY closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | NAGE | TLRY |
|---|---|---|
| FY2025 | $129.4M | $915.5M |
| FY2024 | $99.6M | $821.3M |
| FY2023 | $83.6M | $788.9M |
| FY2022 | $72.0M | $627.1M |
| FY2021 | $67.4M | $628.4M |
| FY2020 | $59.3M | $513.1M |
| FY2019 | $46.3M | $405.3M |
| FY2018 | $31.6M | $179.3M |
| FY2017 | $21.2M | $20.5M |
| FY2016 | $21.7M | $12.6M |
Net income by year
Bottom line
| Fiscal year | NAGE | TLRY |
|---|---|---|
| FY2025 | $17.4M | $-121.4M |
| FY2024 | $8.6M | $-2.2B |
| FY2023 | $-4.9M | $-245.0M |
| FY2022 | $-16.5M | $-1.5B |
| FY2021 | $-27.1M | $-476.8M |
| FY2020 | $-19.9M | $-367.4M |
| FY2019 | $-32.1M | $-102.5M |
| FY2018 | $-33.3M | $-25.0M |
| FY2017 | $-11.4M | $-7.8M |
| FY2016 | $-2.9M | $-7.9M |
More in this industry